A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in
subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be
determined by a Next Generation Sequencing (NGS) test.